Michael J. Schell, PhD

Dr. Schell has led the development of a statistical method to analyze AQUA (Automated Quantitative Analysis)-generated tissue microarray (TMA) data. The method is a 7-step procedure which works quite well for identifying and resolving technical problems when two highly correlated variables are available.  This method provides a practical and efficient way of identifying an appropriate transformation (square-root, quarter-root or log), if needed, of AQUA scores that can be used to satisfy the normality assumption required by most of statistical procedures.  This methodology identifies and adjusts for possible row or column spatial bias effects in a 20 x 17 rectangular plate used in the AQUA machine, which arise due to technical processing effects. The method facilitates the identification of possible outliers or leverage data points in the data due to, for instance, air bubbles. Dr. Schell is a member of the Cancer Biomarkers Study Section.  He is also the statistician for a large integral-biomarker phase III multi-center clinical trial in lung cancer.

• Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723.
• Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
• Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769.
• Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, e-cadherin, bcl-2, and survivin in merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathol. 2012 Aug;34(6):592-596. Pubmedid: 22814318.
• Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
• Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
• Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
• Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?. Sci Rep. 2012;2:765. Pubmedid: 23097687.
• Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Jul;31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
• Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun;64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
• Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG. Suicide in patients with pancreatic cancer. Cancer. 2011 Feb;117(3):642-647. Pubmedid: 20824626.
• Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011 Jan;178(1):69-78. Pubmedid: 21224045. Pmcid: PMC3069904.
• Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma. Int J Cancer. 2010 Dec. Pubmedid: 21154746.
• Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol. 2010 Apr;5(4):484-490. Pubmedid: 20107425. Pmcid: PMC2861290.
• Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr;45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
• Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
• Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2010 Feb;28(2):172-180. Pubmedid: 19968494. Pmcid: PMC3565222.
• Chen JJ, Roberson PK, Schell MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control. 2010 Jan;17(1):58-62. Pubmedid: 20010520.
• Lee J-H, Miladinovic B, Schell MJ. Statistical tutorial notes: analysis of two group comparisons, a practical guide. Med Probl Perform Art. 2009 Dec;166-169.
• Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec;27(34):5808-5815. Pubmedid: 19884554. Pmcid: PMC2793001.
• Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep;8(17):1671-1679. Pubmedid: 19633423.
• Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-333. Pubmedid: 19497997. Pmcid: PMC2708818.
• Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-202. Pubmedid: 19097905.
• Lee JH, Schell MJ, Roetzheim R. Analysis of group randomized trials with multiple binary endpoints and small number of groups. PLoS One. 2009;4(10):e7265. Pubmedid: 19844579. Pmcid: PMC2760209.
• Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul;45(3):150-159. Pubmedid: 18582621.
• Zheng Z, Li X, Schell M, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008 Jun;112(12):2765-2773. Pubmedid: 18442042.
• Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
• Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.
• Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. J Biopharm Stat. 2008;18(5):841-852. Pubmedid: 18781520. Pmcid: PMC2717790.
• Schell M, Yankaskas B, Ballard-Barbash R, Qaqish B, Barlow W, RosenbergRD, Smith-Bindman R. Evidence-based Target Recall Rates for Screening Mammography. Radiology. 2007 Jun;243(3):681-689. Pubmedid: 17517927.
• Pavic D, Schell M, Dancel R, Sultana S, Lin L, Sejpal S, Pisano E. Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients. Acad Radiol. 2007 May;14(5):553-560. Pubmedid: 17434069.
• Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002.
• Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006 May;12(9):2662-2669. Pubmedid: 16675557.
• Stinchcombe T, Choi J, Schell M, Mears A, Jones P, Nachtsheim R, Socinski M. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer. 2006 Feb;51(2):237-243. Pubmedid: 16378657.
• Titus M, Schell M, Lih F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005 Jul;11(13):4653-4657. Pubmedid: 16000557.
• Ivanova A, Qaqish B, Schell M. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-545. Pubmedid: 16011702.
• Titus MA, Gregory CW, Ford OH , Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005 Jun;11(12):4365-4371. Pubmedid: 15958619.
• Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 2005 Jun;115(3):368-376. Pubmedid: 15688379.
• Hensing T, Schell M, Lee J, Socinski M. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb;47(2):253-259. Pubmedid: 15639724.
• Yankaskas B, Schell M, Miglioretti D. Recall and detection rates in screening mammography. Cancer. 2004;101(11):2710-2712. Pubmedid: 15499596.
• Mohler J, Gaston K, Moore D, Schell M, Cohen B, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004;171(6-1):2277-2280. Pubmedid: 15126802.
• Socinski MA, Neubauer MA, Olivares J, Ketchel S, Tynan M, Moore M, Lee JH, Davis K, Schell M, Garfield D. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer. 2003 Apr;40(1):91-97. Pubmedid: 12660013.
• Abrahamson P, Dunlap L, Amamoo M, Schell M, Braeuning M, Pisano E. Factors predicting successful needle-localized breast biopsy. Acad Radiol. 2003;10(6):601-606. Pubmedid: 12809412.
• Hensing T, Peterman A, Schell M, Lee J, Socinski M. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003;98(4):779-788. Pubmedid: 12910523.
• Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002 Nov;76(5):1126-1137. Pubmedid: 12399289.
• McHale M, Berman M, Keefe K, Schell M, Peng Y, Monk B. Influence of Serum and Tissue Micronutrient Levels on the Regression of Untreated Cervical Intraepithelial Neoplasia 2 and 3. J Low Genit Tract Dis. 2002 Oct;6(4):220-224. Pubmedid: 17051026.
• Socikski M, Schell M, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee J, et al.. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20(5):1335-1343. Pubmedid: 11870177.
• Socinski M, Schell M, Bakri K, Peterman A, Lee J, et al.. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 2002;95(6):1265-1273. Pubmedid: 12216094.
• Carter M, Kalwinsky DK, Dahl GV, Santana VM, Mason CA, Schell MJ. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia. 1989 Apr;3(4):298-302. Pubmedid: 2927178.